HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Strowig, S. M. Articles by Raskin, P. Search for Related Content PubMed PubMed Citation Articles by Strowig, S. M. Articles by Raskin, P. Social Bookmarking                What's this?

Improved Glycemic Control Without Weight Gain Using Triple Therapy in Type 2 Diabetes

From the University of Texas Southwestern Medical Center at Dallas, Dallas, Texas

Address correspondence and reprint requests to Suzanne Strowig, University of Texas Southwestern Medical Center at Dallas, 5323 Harry Hines Blvd., Dallas, TX 75390-8858. E-mail: suzanne.strowig{at}utsouthwestern.edu

OBJECTIVE—To evaluate the safety and effectiveness of triple therapy using insulin, metformin, and a thiazolidinedione following a course of dual therapy using insulin and metformin or insulin and a thiazolidinedione in type 2 diabetes.

RESEARCH DESIGN AND METHODS—Twenty-eight type 2 diabetic subjects using insulin monotherapy (baseline HbA_lc level 8.5%) who had been randomly assigned to insulin (INS) and metformin (MET) (INS + MET, n = 14) or INS and the thiazolidinedione troglitazone (TGZ) (INS + TGZ, n = 14) (dual therapy) for 4 months were given INS, MET, and TGZ (triple therapy: INS + MET, add TGZ; or INS + TGZ, add MET) for another 4 months. The INS dose was not increased.

RESULTS—HbA_1c levels decreased in both groups during dual therapy and improved further during triple therapy (INS + MET 7.0 ± 0.8, INS + TGZ 6.2 ± 0.8, P < 0.0001; INS + MET, add TGZ 6.1 ± 0.4%, P < 0.001; INS + TGZ, add MET 5.8 ± 0.6%, P < 0.05; and INS + TGZ vs. INS + MET, P = 0.02). Significant reductions in total daily insulin dose occurred in the INS + TGZ (–14.1 units, P < 0.0001), INS + TGZ add MET (–13.7 units, P < 0.01), and the INS + MET add TGZ groups (–17.3 units, P < 0.003), but not in the INS + MET group (–3.2 units) (INS + TGZ vs. INS + MET P < 0.05). Subjects in the INS + TGZ group experienced significant weight gain (4.4 ± 2.7 kg, P < 0.0005). No weight gain occurred in the INS + MET, INS + MET add TGZ, and INS + TGZ add MET groups.

CONCLUSIONS—Triple therapy using INS, MET, and TGZ resulted in lower HbA_lc levels and total daily insulin dose than during dual therapy. The use of triple therapy resulted in 100% of subjects achieving an HbA_lc <7.0%, while decreasing the dose of INS. Weight gain was avoided when MET therapy preceded the addition of TGZ therapy. The addition of TGZ resulted in the greatest reductions in HbA_lc levels and insulin dose. Triple therapy using INS, MET, and a thiazolidinedione (such as TGZ) can be a safe and effective treatment in type 2 diabetes.

Abbreviations: ALT, alanine aminotransferase • AST, aspartate aminotransferase • INS, insulin • MET, metformin • TGZ, troglitazone

CiteULike    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				A. I. Vinik and Q. Zhang Adding Insulin Glargine Versus Rosiglitazone: Health-related quality-of-life impact in type 2 diabetes Diabetes Care, April 1, 2007; 30(4): 795 - 800. [Abstract] [Full Text] [PDF]

				Z. T. Bloomgarden Achieving Glycemic Goals in Type 2 Diabetes Diabetes Care, January 1, 2007; 30(1): 174 - 180. [Full Text] [PDF]

				D. M. Nathan, J. B. Buse, M. B. Davidson, R. J. Heine, R. R. Holman, R. Sherwin, and B. Zinman Management of Hyperglycemia in Type 2 Diabetes: A Consensus Algorithm for the Initiation and Adjustment of Therapy: A consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes Diabetes Care, August 1, 2006; 29(8): 1963 - 1972. [Full Text] [PDF]

				Z. T. Bloomgarden Insulin Treatment and Type 1 Diabetes Topics Diabetes Care, April 1, 2006; 29(4): 936 - 944. [Full Text] [PDF]

				S. M. Strowig and P. Raskin The Effect of Rosiglitazone on Overweight Subjects With Type 1 Diabetes: Response to Orchard Diabetes Care, March 1, 2006; 29(3): 747 - 747. [Full Text] [PDF]

				J. Meece Dispelling Myths and Removing Barriers About Insulin in Type 2 Diabetes The Diabetes Educator, January 1, 2006; 32(1): 9S - 18S. [Full Text] [PDF]

				M. Malone Medications Associated with Weight Gain Ann. Pharmacother., December 1, 2005; 39(12): 2046 - 2054. [Abstract] [Full Text] [PDF]

				S. M. Strowig and P. Raskin The Effect of Rosiglitazone on Overweight Subjects With Type 1 Diabetes Diabetes Care, July 1, 2005; 28(7): 1562 - 1567. [Abstract] [Full Text] [PDF]

				M. B. Davidson Triple Therapy: Definitions, application, and treating to target Diabetes Care, July 1, 2004; 27(7): 1834 - 1835. [Full Text] [PDF]